Primary Immune Thrombocytopenia Clinical Trial
Official title:
Open, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of Bioven, Manufactured by Biopharma Plasma LLC, in Adult Patients With Chronic Primary Immune Thrombocytopenia (ITP)
The study will involve patients with chronic immune thrombocytopenia. This disease is diagnosed in the presence of isolated thrombocytopenia (decrease in platelet count only), except for other reasons. The addition of "chronic" means that the disease lasts more than 12 months. Patients included in the study will receive Bioven, 10% solution for infusion according to the protocol for the use of IVIG in ITP - at a dose of 0.8-1.0 g / kg 1 time per day for 2 consecutive days, the course dose of 1.6-2.0 g / kg according to the "Guideline on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIG)", rev. 3, 28 June 2018. After administration of the investigational drug, patients will be under medical supervision for 28 days. The stay of patients in the study - at least 4 weeks.
The investigational drug, IVIG, is used for immunomodulatory therapy in the treatment of autoimmune diseases. The study will involve patients with chronic immune thrombocytopenia. This autoimmune disease is diagnosed in the presence of isolated thrombocytopenia (decrease in platelet count only), except for other reasons. The addition of "chronic" means that the disease lasts more than 12 months. Screening stage The patient or her legal representative must sign an informed consent. After the informed consent signing procedure, the patient is screened and assessed for compliance with the inclusion and non-inclusion (exclusion) criteria. Clinical stage After the patient is included in the study, according to the protocol, he/she is hospitalized and the study drug is administered at a dose of 0.8-1.0 g/kg once a day for 2 days (the course dose is 1.6-2.0 g/kg). The next day after the administration of the drug, the patient undergoes blood sampling to determine the level of platelets, the level of immunoglobulin G (IgG) and the Coombs test. This procedure will also be carried out on days 7, 14, 21 and 28 after the first injection of the drug to monitor the patient's performance. The final stage The blood sampling procedure to determine the above indicators will be carried out on days 7, 14, 21, and 28 after the first administration of the drug to monitor the patient's performance. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06466824 -
Observational Study on the Outcome of Patients With ITP Who Underwent Splenectomy After 2010
|
||
| Completed |
NCT05621330 -
Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia
|
Phase 3 | |
| Active, not recruiting |
NCT04278924 -
A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia
|
Phase 2 | |
| Recruiting |
NCT06148389 -
The Safety and Tolerability of STSA-1301 Subcutaneous Injection in Healthy Subjects
|
Phase 1 | |
| Active, not recruiting |
NCT04812925 -
A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
|
Phase 3 | |
| Recruiting |
NCT06107582 -
Longitudinal Cohort of Pediatric Primary Immune Thrombocytopenia (ITP)
|
||
| Recruiting |
NCT05371743 -
Plasma microRNA Levels and Some Cytokines Expression in Patients With ITP Primary Immune Thrombocytopenic Purpura (ITP)
|
||
| Not yet recruiting |
NCT05333861 -
An Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Hetrombopag in Patients With ITP or AA
|
||
| Not yet recruiting |
NCT05311930 -
Efficacy and Safety of TPO Receptor Agonists in the Treatment of Elderly ITP Patients
|
Phase 4 | |
| Completed |
NCT03102593 -
A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP
|
Phase 2 | |
| Completed |
NCT06071520 -
Andalusian Experience in the Use of Fostamatinib in Patients With ITP. FOSTASUR Study
|
||
| Recruiting |
NCT04949009 -
Avatrombopag in the Treatment of Primary Immune Thrombocytopenia(ITP)
|
||
| Terminated |
NCT04224688 -
A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
|
Phase 3 | |
| Active, not recruiting |
NCT04225156 -
A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).
|
Phase 3 | |
| Completed |
NCT05551624 -
Evaluation of the Effect in Platelet Count of Atorvastatin and N-acetyl Cysteine
|
Early Phase 1 | |
| Terminated |
NCT03275740 -
A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347
|
Phase 1 | |
| Terminated |
NCT04596995 -
A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
|
Phase 3 | |
| Terminated |
NCT04200456 -
A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
|
Phase 3 | |
| Recruiting |
NCT05653219 -
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
|
Phase 3 | |
| Completed |
NCT01727232 -
Efficacy and Safety of Rituximab Given at Fixed Dose (1000 mg on Days 1 and 15) Compared to the Standard Regimen in Adult's Immune Thrombocytopenia
|
N/A |